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Abstract: Incidental focal uptake of 18F-fluorodeoxyglucose (FDG) in the thyroid on positron
emission tomography (PET/CT) is rare but often associated with malignancy. The epidemiology of
thyroid incidentalomas has only to some extent been described in countries with iodine deficiency.
Here we report data from Denmark, a country with known iodine deficiency and wide access to
PET/CT. All FDG PET/CT comprising the head and neck region, during 2014, were retrospectively
reviewed, and patients with focal FDG uptake in the thyroid gland were identified. A total of 2451
patients had an FDG PET/CT of which 59 (2.4%) patients presented with FDG-avid focal lesions in
the thyroid gland. Among the 59 patients with FDG-avid lesions, 33 patients (56%) received work up
with ultrasound, thyroid technetium scintigraphy, fine needle aspiration, and/or histology of which
20 patients had a conclusive pathology report. Ten patients with FDG-avid lesions were identified
with thyroid malignancy. The risk of thyroid malignancy was 16.9% among patient with incidental
FDG-avid thyroid lesions. Our findings indicated a similar frequency of FDG thyroid incidentalomas
and malignancy rates in an iodine deficient population compared to summary data from prior studies,
studies mostly performed in geographical areas of normal or excess iodine supplementation.
Keywords: Denmark; incidental findings; iodine deficiency; neoplasms; positron emission
tomography; thyroid
1. Introduction
Incidental imaging findings in a tissue or organ in patients without signs or symptoms of disease in
that tissue (incidentalomas) are frequently occurring [1]. Incidental findings with 18F-fluorodeoxyglucose
positron emission tomography/computer tomography (FDG PET/CT) has been reported in several
tissues [2], including colon [3], prostate [4], breast [5], and the adrenal glands [6].
Thyroid incidentalomas are common in imaging, but the risk of an underlying malignancy varies
greatly depending on the imaging modality used [7] and the proportion of thyroid nodules in the
background population [8]. A notable number of studies and systematic reviews have investigated
the frequency and malignancy rate of FDG-avid thyroid incidentalomas in PET/CT [9–12]. A total
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of 32 original retrospective reports showed a median frequency of 2.3% of FDG-avid lesions in the
populations studied, with thyroid cancer in nearly one in every three patients with focal FDG-avid
thyroid lesions with follow up [12].
Most of the current retrospective studies on FDG incidentalomas have been performed in
countries with normal or excess iodine supply, e.g., USA and South Korea [12–14]. Iodine deficiency
is present in several parts of the World, including many areas of Europe (e.g., Scandinavia), Middle
East, and Africa [14–16]. Low iodine supply may cause a high proportion of thyroid nodules in
the population [8]. Only a few papers on FDG-avid thyroid incidentalomas have been published
from iodine-deficient areas of Europe, namely two papers from Italy [17,18], one from UK [19]
and one from Sweden [20]. These papers have consistently reported frequencies of 1.0–1.8% for
FDG-avid focal lesions, well below the median frequency of 2.3% among the 32 currently published
papers [12]. In contrast, the reported malignancy rates among patients with focal thyroid FDG uptake
and subsequent follow-up in these four papers ranged from 23% in the UK, 34–43% in Italy, to 59% in
Sweden compared to a median proportion of 32% among 32 papers [12].
Several issues warrant additional studies on the epidemiology and malignancy rates of FDG-avid
incidentalomas. First, more studies are required from areas with low iodine supplementation due
to conflicting data of the scarce published reports. In Denmark, up to 39% of women in the age
60–65 years have one or more thyroid nodules over 10 mm on ultrasound [21], but thyroid cancer is
relatively infrequent [22]. Second, the access to PET/CT, and thereby the patient population referred for
FDG PET/CT, varies greatly, even among European countries [23]. The number of PET/CT scanners
and PET/CT examinations per inhabitants in Denmark are among the highest in the World [24].
The purpose of this work was to investigate the frequency and malignancy rates of focal, FDG-avid
thyroid lesions in an iodine-deficient population with wide access to FDG PET/CT.
2. Materials and Methods
2.1. Patients
We retrospectively reviewed all FDG PET/CT that included the head and neck region and were
performed at our institution from 1 January to 31 December 2014. Our department performed PET/CT
for all patients in the Region North, Denmark; an area covering approximately 600,000 inhabitants.
Patients were included in this study if the PET report identified focal FDG-uptake confined to the
thyroid gland, excluding patients with diffuse thyroid FDG uptake. Patients with known malignant
thyroid disease at the time of the PET/CT, as well as patients with a recent fine needle aspiration
of the thyroid were excluded, so were patients with focal FDG uptake in the thyroid shown in any
prior PET/CT. From the electronic medical record system, we registered data from thyroid ultrasound,
thyroid scintigraphy, clinical follow-up, and the description of the pathological sample from the
thyroid (fine needle aspiration of the lesion, pathological examinations of surgical specimens). The data
registration was performed for at least 24 months after the PET/CT and was terminated in October
2017. Any patients with thyroid malignancy proven by pathology within 24 months from the PET/CT
were registered as thyroid malignancy in our study. The Bethesda reporting system for cytopathology
was used [25].
2.2. Imaging Details
The PET/CT was performed on a Discovery VCT scanner (GE Healthcare, Waukesha, WI, USA) in
accordance with institutional procedures. The mean activity of FDG activity was 370 MBq. Blood glucose
levels were less than 11 mmol/L in all patients. The PET/CT was acquired approximately 60 min after
tracer injection. The CT scan was performed as low-dose CT or diagnostic CT with contrast-enhancement.
Classification of pathological FDG uptake in the thyroid was based on clinical impression (relative
uptake in the thyroid versus background and/or asymmetry) and supported by semi-quantitative
analysis of the uptake by calculation of standardized uptake value (SUV). Per institutional practice,
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all FDG PET/CT scans were read independently by two trained hybrid imaging specialists, in most
cases a nuclear medicine physician and a radiologist, and a final diagnosis of pathological FDG uptake
was made in consensus. For this study, the CT scans were used exclusively to verify the thyroidal
confinement of the FDG-avid lesions.
2.3. Approvals
This quality assurance study was approved by the Danish Data Protection Agency at Region
Nordjylland and covered by the general approval obtained by the region (2008-58-0028). The approval
carried a waiver for informed consent to medical files. Retrospective studies do not require approval
by Ethical Committees according to national legislation.
2.4. Statistics
All statistical tests were performed using SPSS ver. 24.0 (SPSS IBM, Armonk, NY, USA). Summary
data are expressed as number and percentage, mean ± standard deviation (SD) or median (range),
depending on the distribution of data.
3. Results
A total of 2451 patients had a PET/CT covering the head and neck region of which 59 (2.4%)
patients presented with an incidental, focal FDG-avid lesion in the thyroid (Table 1). The mean age
of patients with FDG-avid lesions was 69 years, nearly 70% of patients were women, many patients
had a known non-thyroidal cancer at the time of referral, and patients were referred from a variety of
medical specialities. The reason for PET/CT was cancer in most patients (95%), equally distributed
among patients with known cancer and patients suspected of cancer or recurrent cancer.
Table 1. Patient demographics, follow up, and final pathological diagnosis among the 59 patients with
FDG-avid focal thyroid uptake.
Variable Data
Number of patients 59
Age (mean ± SD) 68 ± 9 years
Sex distribution 40 females (68%), 19 males (32%)
Known, non-thyroidal cancer at referral 35 (59%)
Cause of FDG PET/CT
Known cancer (pathology-verified) 29 (49%)
Staging 16
Therapy monitoring 6
Cancer of unknown primary 7
Suspected cancer 27 (46%)
Suspected recurrence 6
Suspected cancer 21
Non-cancer (infection) 3 (5%)
Referring medical specialties
Pulmonary medicine 20 (34%)
Surgical gastroenterology 13 (22%
Oncology/Hematology 9 (15%)
Gynecology 5 (8%)
Otolaryngology 4 (7%)
Other 8 (14%)
Imaging or pathology follow-up 33 (56%)
Thyroid ultrasound 31
Fine needle aspiration 17
Thyroid scintigraphy 15
Surgery 13
Autopsy 1
Abbreviations: FDG PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computer tomography;
SD: Standard deviation.
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Approximately 50% of the patients (n = 33) had imaging and/or pathology follow-up, mostly
with ultrasound. Twenty-one patients had cytology, pathology or both of which 20 (34%) patients had
a definitive cytological or histological diagnosis. One patient was diagnosed with a benign colloid
nodule at autopsy. During a follow up period of two years, ten patients were diagnosed with thyroid
cancer (nine cases of papillary carcinoma and one case of medullary carcinoma). Ten patients had
benign pathology (eight cases of colloid nodules and two cases of thyroiditis). There were no cases of
late thyroid malignancy (>2 years after the PET/CT) in any patients.
The proportion of pathology-proven thyroid malignancy was 16.9% among patients with
FDG-avid thyroid lesions, 30.3% among patients with FDG-avid lesions who received follow-up,
and 50.0% among patients with pathology as reference test (Table 2). Summary data from a recent
systematic review is tabulated in Table 2 for comparison [12].
Table 2. Main findings of this study compared to summary data from 32 retrospective papers presented
in a recent systematic review by Asmar et al. [12].
Populations This Study Asmar et al., 2017(Median and Range) *
Study population, n 2451 4330 (32–49,519)
Patients with incidental, focal FDG-avid thyroid lesions, n 59 80 (19–1.151)
Proportion of patients with FDG-avid thyroid lesions 2.4% 2.3% (0.1–10.1)
Patient with follow up, n 33 38 (11–211)
Proportion of patients with follow up 56% 48% (11–100)
Patients with a conclusive pathology report, n 20
Patients with proven thyroid malignancy, n 10 12 (3–72)
Thyroid malignancy data
Malignancy among patients with FDG-avid lesions 16.9% 13.7% (2.5–55.0)
Malignancy among patient with FDG-avid lesions
and follow-up 30.3% 31.5% (12.4–63.6)
Malignancy among patients with FDG-avid lesions
and conclusive pathology 50.0% Not reported
Abbreviation: FDG: 18F-fluorodeoxyglucose. * Data are captured from individual reports listed in Asmar et al., 2017
and summarized.
Among those 26 patients without follow-up, 21 (84%) patients had a diagnosis of cancer at the
time of the PET/CT or was diagnosed with cancer during the follow-up period. Thirteen patients
died from non-thyroid cancer within one year of the PET/CT. None of the 26 patients were diagnosed
with thyroid malignancy at the end of the observation period. There was no follow-up for thyroid
malignancy among the 2000 or more patients without FDG-avid thyroid lesions. Illustrative examples
of focal FDG uptake are shown in Figure 1.
Thirty-five patients had a non-thyroid cancer at the time of the PET/CT (Table 1, 29 patients with
known cancer referred for PET and 6 patients with suspected recurrence), 13 patients were diagnosed
with malignancy after the PET/CT, including 10 patients with thyroid malignancy, whereas 11 (18.6%)
patients were not diagnosed with any cancer within the observation period after PET/CT.
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Figure 1. (a) A 69-year woman had a 18F-fluorodeoxyglucose positron emission 
tomography/computer tomography (FDG PET/CT) scan because of suspected pancreatic cancer (not 
verified). There was incidental FDG uptake in three lesions in the right thyroid. The patient 
underwent total thyroidectomy; pathology showed papillary adenocarcinoma in all three PET-avid 
lesions. (A) Fused coronal PET/CT images showed intense FDG uptake (standardized uptake value, 
SUV 9.8) in the upper right part of the right thyroid (full white arrow). Another site of pathological 
FDG uptake was seen on this coronal slice as well (dotted white arrow). (B) The CT image showing a 
bilateral nodular goiter with an arrow indicating the site of most intense FDG uptake on the fused 
images. (C + D) Corresponding transverse images of the fused PET/CT images and CT scan with the 
most intense FDG-avid lesion; (b) An FDG PET/CT was performed in a 69-year woman due to 
suspicion of ovarian cancer (confirmed). Incidental FDG uptake was seen in the left lobe. A fine needle 
aspirate showed benign findings (colloid nodule). Any false-negative findings were ruled out during 
clinical and imaging follow. (A) Fused coronal PET/CT images showed intense FDG uptake (SUV 
11.0) in the upper right part of the right thyroid (full white arrow). (B) The CT image showing a 
bilateral nodular goiter with an arrow indicating the most intense site of pathological FDG uptake on 
the fused images. (C + D). Corresponding transverse images of the fused PET/CT images and CT scan 
of the most intense FDG-avid lesion. 
4. Discussion 
Incidental focal increased uptake of FDG in the thyroid on PET/CT has been described in a 
number of studies. However, there is a very limited number of publications from countries with 
documented iodine-deficiency, and these reports have shown conflicting results. To what extent wide 
access to PET/CT had any influence on the epidemiology of FDG PET/CT incidentalomas are not 
previously reported. We assessed the epidemiology of FDG-avid thyroid lesions in Denmark, a 
population deficient of iodine and an unparalleled access to FDG PET/CT for oncology and non-
oncology indications. We concluded that the proportion of FDG-avid thyroid nodules and the 
malignancy rates among the patients in this study were quite similar to data from studies performed 
in the other regions of the World. 
The key findings in this report were demonstration of FDG-avid lesions in 2.4% of the total 
population and the malignancy rates, which were 17% in patients with FDG-avid lesions, 30% among 
patients with focal FDG-avid lesions and follow-up, and 50% in patients who had a conclusive 
cytology/pathology examination. These figures are very similar to data presented in recent systematic 
reviews on thyroid incidental findings by FDG PET/CT [10–12]. Prior reports seldom present data 
among patients with a final pathology examination. These data are available in this report. Absence 
of a final cytological and/or pathological reference, as seen in approximately one-third of the patients, 
was likely caused by ultrasound and/or thyroid scintigraphy findings without suspected nodules. 
It is remarkable that only approximately fifty percent of the patients with FDG-avid lesions 
received follow-up by ultrasound, thyroid scintigraphy and pathology examination by fine needle 
aspiration and/or surgical specimen examination. These findings likely reflect that the majority of the 
Figure 1. (a) A 69-year woman had a 18F-fluorodeoxyglucose positron emission tomography/computer
tomography (FDG PET/CT) scan because of suspected pancreatic cancer (not verified). There was
incidental FDG uptake in three lesions in the right thyroid. The patient underwent total thyroidectomy;
pathology showed papillary adenocarcinoma in all three PET-avid lesions. (A) Fused coronal PET/CT
images showed intense FDG uptake (standardized uptake value, SUV 9.8) in the upper right part of
the right thyroid (full white arrow). Another site of pathological FDG uptake was seen on this coronal
slice as well (dotted white arrow). (B) The CT image showing a bilateral nodular goiter with an arrow
indicating the site of most intense FDG uptake o the fused images. (C + D) Corres onding transverse
i a es of the fused PET/CT images and CT scan with the most intense FDG-avid lesion; (b) An FDG
PET/CT was performed in a 69-year woman due to suspicion of ovarian cancer (confirmed). I ci ental
FDG uptake was seen i the left lobe. A fi e n edle aspirate sho ed benig findings (colloid nodule).
Any false-negative findings were ruled out during clinical and imaging follo . (A) Fused coronal
PET/CT images showed intense FDG uptake (SUV 11.0) in th upper right part of the right thyroid
(full whi e arrow). (B) The CT imag showing a bilateral nodul goiter with an arrow indicating the
mos inte se site of pathological FDG uptake o the fused images. (C + D). Corresponding transv rse
image of the fu ed PET/CT images and CT scan of the mo t intense FDG-avid lesion.
4. Discussion
Incidental focal increased uptake of FDG in the thyroid on PET/CT has been described in a number
of studies. However, there is a very limited number of publications from countries with documented
iodine-deficiency, and these reports have shown conflicting results. To what extent wide access to
PET/CT had any influence on the epidemiology of FDG PET/CT incidentalomas are not previously
reported. We assessed the epidemiology of FDG-avid thyroid lesions in Denmark, a population
deficient of iodine and an unparalleled access to FDG PET/CT for oncology and non-oncology
indications. We concluded that the proportion of FDG-avid thyroid nodules and the malignancy rates
among the patients in this study were quite similar to data from studies performed in the other regions
of the World.
The key findings in this report were demonstration of FDG-avid lesions in 2.4% of the total
population and the malignancy rates, which were 17% in patients with FDG-avid lesions, 30% among
patients with focal FDG-avid lesions and follow-up, and 50% in patients who had a conclusive
cytology/pathology examination. These figures are very similar to data presented in recent systematic
reviews on thyroid incidental findings by FDG PET/CT [10–12]. Prior reports seldom present data
among patients with a final pathology examination. These data are available in this report. Absence of
a final cytological and/or pathological reference, as seen in approximately one-third of the patients,
was likely caused by ultrasound and/or thyroid scintigraphy findings without suspected nodules.
Diagnostics 2018, 8, 46 6 of 9
It is remarkable that only approximately fifty percent of the patients with FDG-avid lesions
received follow-up by ultrasound, thyroid scintigraphy and pathology examination by fine needle
aspiration and/or surgical specimen examination. These findings likely reflect that the majority of the
patients had, or subsequently were diagnosed with, non-thyroid malignancy at an advanced stage
and died within the observation period. Our data confirmed a 50% cancer mortality rate within one
year from the PET/CT in patients without work-up, and a cancer diagnosis in nearly 85% in these
patients. The follow-up data are in line with data from previously published reports as shown in
Table 2 [12].
It remains unclear if data on the epidemiology and malignancy rates of FDG-avid thyroid lesions
are different in geographical areas with iodine-deficiency compared to no deficiency. Most published
studies come from areas with normal or excess iodine supply. We found that 2.4% of the patients
presented with FDG-avid focal lesions, which is similar to data from all regions published in systematic
reviews, as shown in Table 2. However, the frequency of FDA-avid lesions in this report was higher
than previously reported (1.0–1.8%) from other iodine-deficient European countries like Italy [17,18],
UK [19], and Sweden [20]. The malignancy rates among patients with FDG-avid lesions undergoing
follow-up was 30% in this study compared to 34–42% in Italy, 23% in the UK, and 59% in Sweden.
The reasons for this large variation remain speculative, but the composition of the patient population
may be important. Denmark has a very high number of PET/CT scanners, adjusted for population
size, and wide access to PET/CT via free public hospital care without insurance or reimbursement
issues [24]. Less than 60% of the patients in this study had pathology-verified cancer at the time of
the PET/CT, and approximately one in every five patients were not diagnosed with cancer within a
follow-up period of 3 years from the PET. The other studies from iodine-deficient countries included
FDG-avid patients with cancer only [18,20] or included patients with known, as well as suspected
cancer and/or infection without providing specific data by indication for a patient with focal FDG
uptake [17,19]. Finally, the duration of the follow-up period was infrequently described in prior papers.
Even though most thyroid cancers were detected in close relation to the initial work-up, we identified
one patient with thyroid cancer, which was missed during the initial work-up but diagnosed within
two years from the PET/CT.
The prevalence of thyroid nodules may notable influence the prevalence of thyroid incidentalomas,
including FDG-avid lesions. Variation on thyroid nodule prevalences may interfere with
epidemiological data on the frequency and malignancy rates of FDG-avid lesions. Nation-wide
iodine fortification programs have generally been in place for many years in many iodine-deficient
areas, including Denmark where it was initiated in 1997 [8,26]. However, recent follow-up data showed
an inconsistent effect in such programs on iodine excretion, as well as thyroid volume changes [27,28].
Therefore, we as imaging specialists may expect to observe thyroid incidentalomas regularly in the
years to come.
This study reported the frequency of thyroid incidental findings on FDG PET/CT performed as
part of normal clinical practice. Two specialists always read the FDG PET/CT, and the conclusion was
a consensus decision. We always had a radiologist trained in FDG PET to assist in the reading; in this
context, the anatomical reading was of minimal importance, since the CT was mainly used to assure
anatomical localization of incidental findings to the thyroid. The study did not examine observer
variation in the identification of FDG-avid thyroid lesions; the study presented clinical findings as
these were accessible to the referring physician.
Attempts have been made to identify the risk of thyroid malignancy among patients with
FDG-avid lesions, e.g., lesion size and SUV. Such investigations have shown notable variation in
SUV values among groups with malignant and benign thyroid lesions [18–20]. So far, the predictive
values of individual variables remain uncertain. We did no calculations of SUV and/or sizes of
the thyroid lesions. In addition, we did not measure the size of the thyroid incidentalomas, so any
recommendations based on lesion size would be speculative.
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5. Conclusions
In conclusion, we found a low frequency of incidental thyroid lesions with focal increased uptake
of FDG on PET/CT. However, the malignancy rate was high in patients with follow-up (30%), reaching
50% in patients with pathology of the thyroid. Several guidelines recommend work-up of FDG-avid
incidental findings by ultrasound [29,30]. The high rate of thyroid malignancy in patients with
focal FDG-avid lesions suggest that a work-up of such lesions should include at least a fine needle
aspiration cytology.
Author Contributions: N.G., R.V.F. and V.I. conceived and designed the study; N.G., M.G., and L.J.P. collected the
data; N.G., J.K. and L.J.P. analyzed the data; N.G., J.K. and L.J.P. drafted the paper; all authors critically reviewed
and manuscript and approved the final version.
Conflicts of Interest: The authors declare no conflict of interest. Outside this manuscript (and irrespective
if related to the subject matter of this paper), Professor Petersen has received grant support from the Obel
Foundation, has received fees for speaking at meetings arranged by Sanofi-Genzyme, Janssen Pharma, and Bayer;
has been a paid participant in conferences by Sanofi-Genzyme and Bayer; and receives consulting fees from KLIFO
Drug Development Council and ljpmedical. Karmisholt has received fees for speaking at meetings arranged by
Sanofi-Aventis. The other authors declare no conflict of interest.
References
1. Lumbreras, B.; Donat, L.; Hernandez-Aguado, I. Incidental findings in imaging diagnostic tests: A systematic
review. Br. J. Radiol 2010, 83, 276–289. [CrossRef] [PubMed]
2. Tamburello, A.; Treglia, G.; Albano, D.; Bertagna, F.; Giovanella, L. Prevalence and clinical significance of
focal incidental 18F-FDG uptake in different organs: An evidence-based summary. Clin. Transl. Imaging 2017,
5, 525–532. [CrossRef]
3. Kousgaard, S.J.; Thorlacius-Ussing, O. Incidental colorectal FDG uptake on PET/CT scan and lesions observed
during subsequent colonoscopy: A systematic review. Tech. Coloproctol. 2017, 21, 521–529. [CrossRef] [PubMed]
4. Bertagna, F.; Sadeghi, R.; Giovanella, L.; Treglia, G. Incidental uptake of 18F-fluorodeoxyglucose in the
prostate gland. Systematic review and meta-analysis on prevalence and risk of malignancy. Nuklearmedizin
2014, 53, 249–258. [CrossRef] [PubMed]
5. Bertagna, F.; Treglia, G.; Orlando, E.; Dognini, L.; Giovanella, L.; Sadeghi, R.; Giubbini, R. Prevalence
and clinical significance of incidental F18-FDG breast uptake: A systematic review and meta-analysis.
Jpn. J. Radiol. 2014, 32, 59–68. [CrossRef] [PubMed]
6. Wong, K.K.; Arabi, M.; Bou-Assaly, W.; Marzola, M.C.; Rubello, D.; Gross, M.D. Evaluation of incidentally
discovered adrenal masses with pet and PET/CT. Eur. J. Radiol. 2012, 81, 441–450. [CrossRef] [PubMed]
7. Uppal, A.; White, M.G.; Nagar, S.; Aschebrook-Kilfoy, B.; Chang, P.J.; Angelos, P.; Kaplan, E.L.; Grogan, R.H.
Benign and malignant thyroid incidentalomas are rare in routine clinical practice: A review of 97,908 imaging
studies. Cancer Epidemiol. Biomark. Prev. 2015, 24, 1327–1331. [CrossRef] [PubMed]
8. Carle, A.; Krejbjerg, A.; Laurberg, P. Epidemiology of nodular goitre. Influence of iodine intake. Best Pract.
Res. Clin. Endocrinol. Metab. 2014, 28, 465–479. [CrossRef] [PubMed]
9. Bertagna, F.; Treglia, G.; Piccardo, A.; Giubbini, R. Diagnostic and clinical significance of F-18-FDG-PET/CT
thyroid incidentalomas. J. Clin. Endocrinol. Metab. 2012, 97, 3866–3875. [CrossRef] [PubMed]
10. Soelberg, K.K.; Bonnema, S.J.; Brix, T.H.; Hegedus, L. Risk of malignancy in thyroid incidentalomas detected
by 18F-fluorodeoxyglucose positron emission tomography: A systematic review. Thyroid 2012, 22, 918–925.
[CrossRef] [PubMed]
11. Nayan, S.; Ramakrishna, J.; Gupta, M.K. The proportion of malignancy in incidental thyroid lesions on
18-FDG PET study: A systematic review and meta-analysis. Otolaryngol. Head Neck Surg. 2014, 151, 190–200.
[CrossRef] [PubMed]
12. Asmar, A.; Simonsen, L.; Bulow, J.; Asmar, M. Work-up of thyroid incidentalomas identified by
18F-fluorodeoxyglucose PET/CT. Ugeskr. Laeger 2017, 179.
Diagnostics 2018, 8, 46 8 of 9
13. Kang, M.J.; Hwang, I.T.; Chung, H.R. Excessive iodine intake and subclinical hypothyroidism in children
and adolescents aged 6–19 years: Results of the sixth korean national health and nutrition examination
survey, 2013–2015. Thyroid 2018, 28, 773–779. [CrossRef] [PubMed]
14. World Health Organization. Iodine Status Worldwide. Country Data on Median Urinary Iodine
Concentrations and Urinary Iodine Concentrations in School Age Children <100 µg/L 1993–2006.
Available online: http://www.who.int/vmnis/iodine/status/summary/IDD_estimates_table_2007.pdf?
ua=1 (accessed on 28 May 2018).
15. De Benoist, B.; McLean, E.; Andersson, M.; Rogers, L. Iodine deficiency in 2007: Global progress since 2003.
Food Nutr. Bull. 2008, 29, 195–202. [CrossRef] [PubMed]
16. Manousou, S.; Dahl, L.; Heinsbaek Thuesen, B.; Hulthen, L.; Nystrom Filipsson, H. Iodine deficiency
and nutrition in scandinavia. Min. Med. 2017, 108, 147–158.
17. Pagano, L.; Sama, M.T.; Morani, F.; Prodam, F.; Rudoni, M.; Boldorini, R.; Valente, G.; Marzullo, P.; Baldelli, R.;
Appetecchia, M.; et al. Thyroid incidentaloma identified by (1)(8)F-fluorodeoxyglucose positron emission
tomography with CT (FDG-PET/CT): Clinical and pathological relevance. Clin. Endocrinol. 2011, 75, 528–534.
[CrossRef] [PubMed]
18. Bertagna, F.; Treglia, G.; Piccardo, A.; Giovannini, E.; Bosio, G.; Biasiotto, G.; Bahij, E.K.; Maroldi, R.;
Giubbini, R. F18-FDG-PET/CT thyroid incidentalomas: A wide retrospective analysis in three Italian centres
on the significance of focal uptake and suv value. Endocrine 2013, 43, 678–685. [CrossRef] [PubMed]
19. Brindle, R.; Mullan, D.; Yap, B.K.; Gandhi, A. Thyroid incidentalomas discovered on positron emission
tomography CT scanning—Malignancy rate and significance of standardised uptake values. Eur. J.
Surg. Oncol. 2014, 40, 1528–1532. [CrossRef] [PubMed]
20. Nilsson, I.L.; Arnberg, F.; Zedenius, J.; Sundin, A. Thyroid incidentaloma detected by fluorodeoxyglucose
positron emission tomography/computed tomography: Practical management algorithm. World J. Surg.
2011, 35, 269–2697. [CrossRef] [PubMed]
21. Knudsen, N.; Bulow, I.; Jorgensen, T.; Laurberg, P.; Ovesen, L.; Perrild, H. Goitre prevalence and thyroid
abnormalities at ultrasonography: A comparative epidemiological study in two regions with slightly
different iodine status. Clin. Endocrinol. 2000, 53, 479–485. [CrossRef]
22. Londero, S.C.; Krogdahl, A.; Bastholt, L.; Overgaard, J.; Pedersen, H.B.; Frisch, T.; Bentzen, J.; Pedersen, P.U.;
Christiansen, P.; Godballe, C. Papillary thyroid carcinoma in denmark 1996–2008: An investigation of
changes in incidence. Cancer Epidemiol. 2013, 37, e1–e6. [CrossRef] [PubMed]
23. Cuocolo, A.; Breatnach, E. Multimodality imaging in europe: A survey by the european association of
nuclear medicine (EANM) and the european society of radiology (ESR). Eur. J. Nucl. Med. Mol. Imaging 2010,
37, 163–167. [CrossRef] [PubMed]
24. Hoilund-Carlsen, P.F.; Gerke, O.; Vilstrup, M.H.; Nielsen, A.L.; Thomassen, A.; Hess, S.; Hoilund-Carlsen, M.;
Vach, W.; Petersen, H. PET/CT without capacity limitations: A danish experience from a european
perspective. Eur. Radiol. 2011, 21, 1277–1285. [CrossRef] [PubMed]
25. Cibas, E.S.; Ali, S.Z. The bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 2009, 132,
658–665. [CrossRef] [PubMed]
26. Laurberg, P.; Jorgensen, T.; Perrild, H.; Ovesen, L.; Knudsen, N.; Pedersen, I.B.; Rasmussen, L.B.; Carle, A.;
Vejbjerg, P. The danish investigation on iodine intake and thyroid disease, danthyr: Status and perspectives.
Eur. J. Endocrinol. 2006, 155, 219–228. [CrossRef] [PubMed]
27. Rasmussen, L.B.; Carle, A.; Jorgensen, T.; Knuthsen, P.; Krejbjerg, A.; Perrild, H.; Bjergved, L.; Sloth, J.J.;
Laurberg, P.; Ovesen, L. Iodine excretion has decreased in denmark between 2004 and 2010—The importance
of iodine content in milk. Br. J. Nutr. 2014, 112, 1993–2001. [CrossRef] [PubMed]
28. Krejbjerg, A.; Bjergved, L.; Pedersen, I.B.; Carle, A.; Jorgensen, T.; Perrild, H.; Ovesen, L.; Rasmussen, L.B.;
Knudsen, N.; Laurberg, P. Iodine fortification may influence the age-related change in thyroid volume:
A longitudinal population-based study (DanThyr). Eur. J. Endocrinol. 2014, 170, 507–517. [CrossRef]
[PubMed]
Diagnostics 2018, 8, 46 9 of 9
29. Horvath, E.; Silva, C.F.; Majlis, S.; Rodriguez, I.; Skoknic, V.; Castro, A.; Rojas, H.; Niedmann, J.P.; Madrid, A.;
Capdeville, F.; et al. Prospective validation of the ultrasound based TIRADS (Thyroid Imaging Reporting
And Data System) classification: Results in surgically resected thyroid nodules. Eur. Radiol. 2017, 27,
2619–2628. [CrossRef] [PubMed]
30. Russ, G.; Leboulleux, S.; Leenhardt, L.; Hegedus, L. Thyroid incidentalomas: Epidemiology, risk stratification
with ultrasound and workup. Eur. Thyroid J. 2014, 3, 154–163. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
